

# Giulia Renda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4679585/publications.pdf>

Version: 2024-02-01

68  
papers

2,399  
citations

236833

25  
h-index

214721

47  
g-index

75  
all docs

75  
docs citations

75  
times ranked

3584  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1295-1301.	1.2	252
2	Awake Systolic Blood Pressure Variability Correlates With Target-Organ Damage in Hypertensive Subjects. <i>Hypertension</i> , 2007, 50, 325-332.	1.3	251
3	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017, 135, 1273-1275.	1.6	133
4	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE-AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1372-1382.	1.2	111
5	Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 264-274.	2.3	103
6	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1363-1371.	1.2	102
7	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A "state-of-the-art" paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223.	1.0	78
8	Awake Blood Pressure Variability, Inflammatory Markers and Target Organ Damage in Newly Diagnosed Hypertension. <i>Hypertension Research</i> , 2008, 31, 2137-2146.	1.5	75
9	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019, 16, 113-130.	6.1	73
10	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 409-419.	1.2	67
11	Rapid Decline of Collateral Circulation Increases Susceptibility to Myocardial Ischemia. <i>Journal of the American College of Cardiology</i> , 2006, 48, 59-65.	1.2	62
12	Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences. <i>Arthritis and Rheumatism</i> , 2011, 63, 850-859.	6.7	56
13	Genetic determinants of blood pressure responses to caffeine drinking. <i>American Journal of Clinical Nutrition</i> , 2012, 95, 241-248.	2.2	54
14	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017, 38, ehw159.	1.0	53
15	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019, 132, 749-757.e5.	0.6	48
16	Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 672-681.	2.3	47
17	Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents. <i>Drugs</i> , 2005, 65, 725-732.	4.9	38
18	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.	0.8	38

#	ARTICLE	IF	CITATIONS
19	Increased short-term blood pressure variability is associated with early left ventricular systolic dysfunction in newly diagnosed untreated hypertensive patients. <i>Journal of Hypertension</i> , 2013, 31, 1653-1661.	0.3	36
20	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010, 31, 2133-2140.	1.0	35
21	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.	1.6	35
22	Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. <i>American Journal of Medicine</i> , 2015, 128, 1007-1014.e2.	0.6	32
23	Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 115-125.	2.3	27
24	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , 2014, 100, 1625-1635.	1.2	27
25	Genetic determinants of cognitive responses to caffeine drinking identified from a double-blind, randomized, controlled trial. <i>European Neuropsychopharmacology</i> , 2015, 25, 798-807.	0.3	27
26	Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. <i>Journal of Clinical Medicine</i> , 2020, 9, 1120.	1.0	26
27	Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009375.	2.1	26
28	CHA <sub>2</sub> DS <sub>2</sub> -VASc score and adverse outcomes in middle-aged individuals without atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1987-1997.	0.8	25
29	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. <i>International Journal of Cardiology</i> , 2018, 270, 160-166.	0.8	24
30	The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?. <i>Vascular Pharmacology</i> , 2013, 59, 53-62.	1.0	23
31	Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. <i>International Journal of Cardiology</i> , 2019, 286, 198-207.	0.8	23
32	Prognostic Significance of Chest Imaging by LUS and CT in COVID-19 Inpatients: The ECOVID Multicenter Study. <i>Respiration</i> , 2022, 101, 122-131.	1.2	23
33	Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1773-1784.	1.8	22
34	Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery. <i>Haematologica</i> , 2007, 92, 366-373.	1.7	21
35	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 74-84.	0.7	21
36	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. <i>EuroIntervention</i> , 2021, 17, 59-66.	1.4	21

#	ARTICLE	IF	CITATIONS
37	Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1984-1986.	1.2	18
38	Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. <i>Haematologica</i> , 2010, 95, 2095-2101.	1.7	17
39	Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis. <i>American Journal of Medicine</i> , 2017, 130, 457-461.	0.6	17
40	Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 782-790.	1.0	17
41	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	1.2	16
42	Prognostic significance of noncardiac syncope in the general population: A systematic review and meta-analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1641-1647.	0.8	16
43	Facilitated PCI: Rationale, Current Evidence, Open Questions, and Future Directions. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 51, 3-10.	0.8	15
44	Mortality Prediction of the CHA2DS2-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3987.	1.0	15
45	Measurements of thromboxane production and their clinical significance in coronary heart disease. <i>Thrombosis and Haemostasis</i> , 2012, 108, 6-8.	1.8	14
46	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016, 129, 1117-1123.e2.	0.6	14
47	Predictors of Mortality and Cardiovascular Outcome at 6 Months after Hospitalization for COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 729.	1.0	14
48	Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future. <i>Current Pharmaceutical Design</i> , 2012, 18, 5215-5223.	0.9	12
49	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , 2020, 318, 67-73.	0.8	11
50	Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination. <i>Thrombosis and Haemostasis</i> , 2004, 92, 668-669.	1.8	9
51	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 642-651.	0.7	9
52	Predictive Value of Left Atrial and Ventricular Strain for the Detection of Atrial Fibrillation in Patients With Cryptogenic Stroke. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 869076.	1.1	9
53	Aspirin-triggered lipoxin in patients treated with aspirin and selective/nonselective COX-2 inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 303-306.	1.1	7
54	The predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3145.	1.7	5

#	ARTICLE	IF	CITATIONS
55	New anticoagulants for atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 446-453.	0.6	4
56	Impact of Antiplatelet Therapy in Heart Disease. <i>Advances in Cardiology</i> , 2012, 47, 5-19.	2.6	4
57	Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review. <i>Cor Et Vasa</i> , 2017, 59, e277-e281.	0.1	4
58	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 591-599.	1.0	4
59	Sex Implications in the Response to Anticoagulant Therapy in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 283-286.	1.2	3
60	Clustering of blood cell count abnormalities and future risk of death. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13562.	1.7	3
61	Case Report: Mitral Valve Involvement and First-Degree Atrial-Ventricular Block in Two Patients With Multisystem Inflammatory Syndrome in Children. <i>Frontiers in Pediatrics</i> , 2021, 9, 676934.	0.9	3
62	Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination. <i>Thrombosis and Haemostasis</i> , 2004, 92, 668-9.	1.8	3
63	Prevention of contrast-induced nephropathy with urine alkalization: the TEATE study design. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 65-72.	0.6	2
64	The legacy of ISCHEMIA. <i>Cardiology Journal</i> , 2020, 27, 329-335.	0.5	1
65	Coffee and Hypertension. , 2015, , 395-402.		0
66	Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111783.	2.5	0
67	Access Site Bleeding Complications with NOACs versus VKAs in Patients with Atrial Fibrillation Undergoing Cardiac Implantable Device Intervention. <i>Journal of Clinical Medicine</i> , 2022, 11, 986.	1.0	0
68	A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 1945.	1.0	0